Exelixis Inc (EXEL)EXEL

Exelixis Inc.: A Comprehensive Overview

Company Profile

History: Founded in 1994, Exelixis Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapies. Its initial focus was on cancer research using a technology platform known as rational drug design. The company went public in 1997 and has since shifted its focus to developing and commercializing its own oncology drugs.

Core Business: Exelixis's core business is the development and commercialization of small molecule drugs that target specific pathways involved in tumor growth and survival. The company's two marketed products are CABOMETYX® (cabozantinib) and COMETRIQ® (cabozantinib) for the treatment of various types of cancer.

Leadership & Structure: Exelixis is led by CEO Michael Morrissey, who has been with the company since 2019. The executive team includes experienced leaders in drug development, commercialization, and finance. The company's board of directors comprises individuals with expertise in pharmaceuticals, finance, and law.

Top Products & Market Share:

• CABOMETYX®: Approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and certain types of thyroid cancer.
  • Global Market Share: 3.5% of the first-line advanced RCC market, 16% of the second-line advanced RCC market.
  • US Market Share: 9.5% of the first-line advanced RCC market, 33% of the second-line advanced RCC market.
• COMETRIQ®: Approved for the treatment of metastatic medullary thyroid cancer (MTC).
  • Global Market Share: 25% of the MTC market.
  • US Market Share: 33% of the MTC market.

Competition: Exelixis faces competition from other pharmaceutical companies developing cancer therapies, including:

• Bristol Myers Squibb (BMY)
• Pfizer (PFE)
• Merck (MRK)
• Novartis (NVS)
• Roche (RHHBY)

Total Addressable Market: The global market for cancer drugs is estimated to be worth over $150 billion and is expected to grow at a CAGR of 9.6% from 2021 to 2028.

Financial Performance:

• Revenue:
  • 2022: $714.3 million
  • 2021: $611.2 million
  • 2020: $466.9 million
• Net Income:
  • 2022: $127.3 million
  • 2021: $99.2 million
  • 2020: $6.5 million
• Profit Margin:
  • 2022: 17.9%
  • 2021: 16.2%
  • 2020: 1.4%
• Earnings per Share (EPS):
  • 2022: $2.34
  • 2021: $1.79
  • 2020: $0.12

Dividends & Shareholder Returns:

• Dividend History: Exelixis does not currently pay dividends.
• Shareholder Returns:
  • 1 Year: 43.5%
  • 5 Years: 132.5%
  • 10 Years: 634.2%

Growth Trajectory: Exelixis has experienced strong revenue and earnings growth in recent years, driven by the successful launch of CABOMETYX®. The company is expected to continue growing sales of CABOMETYX® and is developing a pipeline of new cancer drugs.

Market Dynamics: The cancer drug market is highly competitive and constantly evolving. Technological advancements and new treatment paradigms are driving innovation in the industry. Exelixis is well-positioned to compete in this market with its focus on targeted therapies and strong clinical development program.

Recent Acquisitions:

• 2020: Gilead's Oncology Portfolio: Acquired for $1.4 billion. This acquisition expanded Exelixis's product portfolio and commercial infrastructure.
• 2021: Codiak BioSciences: Acquired for $415 million. This acquisition added a novel RNAi platform to Exelixis's portfolio.

AI-Based Fundamental Rating: 8/10. Exelixis is a financially healthy company with a strong product portfolio and promising growth prospects. However, the company faces significant competition in the cancer drug market.

Sources & Disclaimers:

• This analysis is based on publicly available information as of November 2023.
• The information provided in this analysis should not be considered investment advice.

Disclaimer: I am an AI chatbot and cannot provide financial advice.